News & Updates
Filter by Specialty:

Switch to B/F/TAF maintains viral suppression in people with HIV-1, HBV
20 Mar 2025
byStephen Padilla
Following the switch from dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF), treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has shown efficacy in keeping HIV-1 and hepatitis B virus (HBV) at low levels in the blood through 48 weeks of the open-label extension (OLE) phase of the ALLIANCE study.
Switch to B/F/TAF maintains viral suppression in people with HIV-1, HBV
20 Mar 2025
Children with post-COVID syndrome carry socio-educational burden
10 Mar 2025
byStephen Padilla
Paediatric post-COVID syndrome (pPCS) brings a substantial socio-educational burden that must be included in medical, social, and educational care, suggests a study.